The Preventive Effect of Shenfu Injection on Myocardial Dysfunction in Sepsis
Launched by FIRST AFFILIATED HOSPITAL OF WANNAN MEDICAL COLLEGE · Mar 21, 2025
Trial Information
Current as of April 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a treatment called Shenfu Injection in patients with septic shock, a serious condition caused by severe infections that can harm the heart. The goal is to see if adding Shenfu Injection to the usual treatments can help prevent heart problems, speed up recovery if heart issues do occur, and ultimately improve survival rates for patients. Participants will be divided into two groups: one will receive standard treatment for septic shock, while the other will receive that same treatment along with Shenfu Injection.
To be eligible for this trial, patients must be at least 18 years old and diagnosed with septic shock. However, certain individuals, such as pregnant women, those with severe heart conditions, or patients with other serious health issues, cannot participate. If you or someone you know is considering joining this trial, they can expect to receive close monitoring and care from healthcare professionals as part of the study. This trial is currently recruiting participants and aims to make a significant difference in how septic shock is managed.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients clinically diagnosed with septic shock must meet the diagnostic criteria of Sepsis 3.0;
- • 2. Age ≥ 18 years.
- Exclusion Criteria:
- • 1. Pregnant or breastfeeding women;
- • 2. Individuals with a history of allergies or known hypersensitivity to Ginseng and Aconite Injection or its components;
- • 3. Severe underlying diseases that may affect prognosis, including uncontrolled malignant tumors with multiple metastases that are unresectable, hematological disorders, cachexia, persistent active bleeding, severe malnutrition, HIV, etc.;
- • 4. Severe cardiac conditions within the last three months, including acute unstable myocardial infarction, dilated cardiomyopathy, acute coronary syndrome, acute or chronic valvular heart disease, and congestive heart failure (New York Heart Association \[NYHA\] Class IV);
- • 5. Any of the following medical procedures performed within the last three months: any form of cardiac surgery, thoracotomy, external cardiac compression, defibrillation, direct current cardioversion, or trauma;
- • 6. Use of Ginseng and Aconite Injection for less than 48 hours;
- • 7. Patients expected to die within 48 hours;
- • 8. Patients deemed unsuitable for this study by the investigator.
About First Affiliated Hospital Of Wannan Medical College
The First Affiliated Hospital of Wannan Medical College is a leading medical institution dedicated to advancing healthcare through innovative clinical research and patient-centered care. With a strong commitment to academic excellence and collaboration, the hospital serves as a pivotal research hub, facilitating a wide range of clinical trials aimed at improving patient outcomes and enhancing medical knowledge. Equipped with state-of-the-art facilities and a multidisciplinary team of experienced healthcare professionals, the hospital fosters an environment of rigorous scientific inquiry and ethical standards, ensuring the highest quality of care and research integrity.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wuhu, Anhui, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported